Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer

Patricia Mae G. Santos, Xingzhe Li, Daniel R. Gomez

Research output: Contribution to journalReview articlepeer-review


In the last 20 years, significant strides have been made in our understanding of the biological mechanisms driving disease pathogenesis in metastatic non-small cell lung cancer (NSCLC). Notably, the development and application of predictive biomarkers as well as refined treatment regimens in the form of chemoimmunotherapy and novel targeted agents have led to substantial improvements in survival. Parallel to these remarkable advancements in modern systemic therapy has been a growing recognition of “oligometastatic disease” as a distinct clinical entity—defined by the presence of a controlled primary tumor and ≤5 sites of metastatic disease amenable to local consolidative therapy (LAT), with surgery or stereotactic ablative body radiotherapy (SABR). To date, three randomized studies have provided clinical evidence supporting the use of LAT/SABR in the treatment of oligometastatic NSCLC. In this review, we summarize clinical evidence from these landmark studies and highlight ongoing trials evaluating the use of LAT/SABR in a variety of clinical contexts along the oligometastatic disease spectrum. We discuss important implications and caveats of the available data, including considerations surrounding patient selection and application in routine clinical practice. We conclude by offering potential avenues for further investigation in the oligometastatic disease space.

Original languageEnglish (US)
Article number3977
Issue number16
StatePublished - Aug 2022
Externally publishedYes


  • local ablative therapy (LAT)
  • lung cancer
  • metastatic disease
  • non-small cell lung cancer (NSCLC)
  • oligometastatic disease
  • oligoprogression
  • stereotactic ablative therapy (SABR)
  • stereotactic body radiotherapy (SBRT)

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Local Consolidative Therapy for Oligometastatic Non-Small Cell Lung Cancer'. Together they form a unique fingerprint.

Cite this